Lupin was bound downward today after the company announced an 83.6% drop in net profit for Q4.
The poor results compelled a 2.70% fall to Rs 163.95 in the scrip of the Indian drugs maker by 9:58 IST. By then, volumes of 19,585 Lupin shares were recorded on BSE.
On Tuesday, after market hours, Lupin said Q4 ended 31 March 2003 net profit slumped 83.6% to Rs 2.28 crore (Rs 13.90 crore) on a 20.4% increase in total income to Rs 269.24 crore (Rs 223.66 crore).
Pricing pressure and price cuts by the NPPA in the TB segment have supposedly done the company in. Despite the decent sales performance, the bottom line has been affected by poor realisations.
For FY 2002-03, the company recorded a 1.23% rise in net profit to Rs 73.07 crore (Rs 72.18 crore) on a 19% increase in total income to Rs 1,041.11 crore (Rs 875.83 crore). On a consolidated basis, the company's net profit works out to Rs 74.30 crore (Rs 73.69 crore) on total income of Rs 1,121.84 crore (Rs 980.43 crore).
The company's board has also recommended a dividend of 50% (Rs 5 per share on a face value of Rs 10 ) for FY 2002-03.
Lupin's strength in the domestic market can best be indicated by the fact that it has eight or more brands in the top 300 brands in India. Further over 20 of its brands are in the top three brands in their respective categories. Likewise, in every product in which the company has targeted the global market, it is among the top 3 global players. Further, in many markets that are not expanding, Lupin's market share is expanding due to its quality and cost advantages.
The company has eight manufacturing plants, of which seven have been approved by USFDA. Many of its plants are also approved by MCA.
As on 31 March 2003, the promoters held 67.22% stake in the company, while the public and institutions held 23.04% and 4.54% stake, respectively.
© 2026